Featured News September 22, 2026Ophirex Publishes Data from Phase 2 BRAVIO Trial Evaluating Intravenous Followed by Oral Varespladib for SnakebiteOphirex, Inc., a Public Benefit Corporation developing novel treatments for snakebite envenomation, today announced the publication of results from the Phase 2 BRAVIO clinical trial in PLOS Neglected Tropical Diseases. The trial evaluated the efficacy and safety of intravenous sodium varespladib followed by oral methyl varespladib, added to standard antivenom therapy, in patients with snakebite envenomation in India and the United States.Press Releases Featured Media Load More
September 22, 2026Ophirex Publishes Data from Phase 2 BRAVIO Trial Evaluating Intravenous Followed by Oral Varespladib for SnakebiteOphirex, Inc., a Public Benefit Corporation developing novel treatments for snakebite envenomation, today announced the publication of results from the Phase 2 BRAVIO clinical trial in PLOS Neglected Tropical Diseases. The trial evaluated the efficacy and safety of intravenous sodium varespladib followed by oral methyl varespladib, added to standard antivenom therapy, in patients with snakebite envenomation in India and the United States.
